Shockwave Medical Appoints Nick West as Associate Chief Medical Officer
12 Setembro 2023 - 9:00AM
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the
development and commercialization of transformational technologies
for the treatment of cardiovascular disease, announced today that
Nick West, MA, MD, FRCP, FESC, FACC, has joined the company in the
role of Associate Chief Medical Officer. Dr. West will report to
Keith Dawkins, MD, Chief Medical Officer, and will be based in
Santa Clara, with plans to succeed Dr. Dawkins as CMO in mid-2024.
“Dr. West brings to Shockwave a wealth of expertise in the
interventional cardiology space,” said Dr. Dawkins. “Having known
Nick for many years, I am confident that his expertise will be
highly influential in further developing Intravascular Lithotripsy
(IVL) as the standard of care for calcium modification, and will
also be a valued asset in the evaluation and development of novel
transformational technologies to augment our portfolio in the years
to come.”
Dr. West joins Shockwave from Abbott Vascular, where he served
as Chief Medical Officer and Divisional Vice President of Global
Medical Affairs for the past four years. Prior to his time with
Abbott, Dr. West served as an attending cardiologist at the Royal
Papworth Hospital NHS Foundation Trust in Cambridge, United
Kingdom.
“There is no denying the exceptional job Shockwave has done to
generate significant momentum behind IVL in a relatively short
period of time. I am extremely excited to utilize everything I have
learned from my time both in industry and previously as an
interventional cardiologist to help continue to propel Shockwave
forward as one of the most innovative players in the cardiovascular
space," said Dr. West. “I look forward to contributing to the
company’s mission of developing exceptional solutions to
revolutionize treatments for underserved patient populations.”
Dr. West graduated in medicine from Trinity Hall, University of
Cambridge and St. Thomas’ Hospital Medical School, London, and
trained in interventional cardiology at the John Radcliffe
Hospital, Oxford and Green Lane Hospital, Auckland, New Zealand. He
has published over 170 peer-reviewed papers and book chapters on
topics including vascular biology, coronary
physiology/microvascular function, intracoronary imaging/vulnerable
plaque detection, and bioresorbable scaffold technology. He is a
founding member and Chief Medical Officer of the Cambridge-based
vulnerable plaque startup, PlaqueTec Ltd, and sits on the
Innovation Council of the UCLA School of Biodesign.
Dr. West was also a co-author of the ILUMIEN IV late-breaking
clinical trial presented at the European Society of Cardiology
Congress last month. “His expertise in intravascular imaging will
be especially beneficial to many Shockwave IVL customers as the use
of imaging continues to increase, and, as a result, there arises a
greater appreciation for the presence and diverse morphology of
cardiovascular calcium,” Dr. Dawkins concluded.
About Shockwave Medical, Inc. Shockwave
Medical is a leader in the development and commercialization
of novel technologies that transform the care of underserved
patients with cardiovascular disease. Its first-of-its-kind
Intravascular Lithotripsy (IVL) technology has revolutionized the
way calcium is managed during the treatment of atherosclerotic
cardiovascular disease by safely using sonic pressure waves to
disrupt challenging calcified plaque, resulting in significantly
improved patient outcomes. Through the recent acquisition of the
Reducer, which is under clinical investigation in the
U.S. and is CE Marked in the EU and UK, Shockwave
Medical plans to introduce its second transformative technology to
the interventional cardiology community. By redistributing blood
flow within the heart, the Reducer is designed to provide relief to
the millions of patients worldwide suffering from refractory angina
who have no other treatment options. Learn more
at www.shockwavemedical.com and www.neovasc.com.
Forward-Looking StatementsThis press release
contains statements relating to our expectations, activities,
programs, goals, events or developments that we expect, believe or
anticipate will or may occur, which are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements, other than statements of
historical facts, are statements that could be deemed
forward-looking. In some cases, you can identify these statements
by forward-looking words such as “may,” “might,” “will,” “should,”
“expects,” “plans,” “anticipates,” “believes,” “estimates,”
“predicts,” “potential,” or “continue,” and similar expressions,
and the negative of these terms. You are cautioned not to place
undue reliance on these forward-looking statements. Forward-looking
statements are only predictions based on our current plans,
expectations, estimates, and assumptions, valid only as of the date
they are made, and subject to risks and uncertainties, some of
which we are not currently aware.
Important factors that could cause our actual results to differ
materially from those indicated in the forward-looking statements
include, among others: our ability to design, develop, manufacture
and market innovative products to treat patients with challenging
medical conditions, particularly in peripheral artery disease,
coronary artery disease and aortic stenosis; our ability to
successfully execute our commercialization strategy for our
approved or cleared products; and our expected future growth,
including growth in international sales. These factors, as well as
others, are discussed in our filings with the Securities and
Exchange Commission (SEC), including in Part I, Item IA - Risk
Factors in our most recent Annual Report on Form 10-K filed with
the SEC, and in our other periodic and other reports filed with the
SEC. Except to the extent required by law, we do not undertake to
update any of these forward-looking statements after the date
hereof to conform these statements to actual results or revised
expectations.
Media Contact:Scott
Shadiow+1.317.432.9210sshadiow@shockwavemedical.comInvestor
Contact:Debbie Kasterdkaster@shockwavemedical.com
Shockwave Medical (NASDAQ:SWAV)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Shockwave Medical (NASDAQ:SWAV)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024